Overview

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Afatinib
Prednisone